Last year, the Indian Patent Office (IPO) reported filing of eight (8) post-grant opposition applications under section 25 (2) of the Patents Act, 1970. The post-grant opposition can be filed against any granted Indian patent within twelve (12) months from the date of publication of grant. List of patents that are opposed under section 25 (2) in 2009 are:
(1) IN214103: Torrent Pharmaceuticals Limited filed opposition on January 30, 2009 against Sankyo/UBE Industries Limited’s Indian Patent No. 214103 protecting pharmaceutical compositions containing Prasugrel and Aspirin for prevention of diseases caused by thrombus or embolus. Prasugrel, marketed as Efient by Eli Lilly is a novel platelet inhibitor approved for use with acetylsalicylic acid (aspirin) for the prevention of atherothrombotic events in patients with acute coronary syndrome (ACS).
(2) IN221171: Cipla Limited filed opposition on February 16, 2009 against Glaxo’s Indian Patent No. 221171 covering Ditosylate salt of anti-cancer drug compound Lapatinib. Lapatinib Ditosylate is active ingredient of Tykerb approved for the combination therapy for breast cancer patients already using capecitabine.
(3) IN220257: Enercon (
(4) IN216080: Cipla Limited filed opposition on March 06, 2009 against Ivax’s Indian Patent No. 216080 protecting Budesonide and Formoterol combination HFA aerosol formulation.
(5) IN217464: Emcure Pharmaceuticals limited filed opposition on March 27, 2009 against Eli Lilly’s Indian Patent No. 217464 protecting Olanzapine lyophilized product for parenteral administration.
(6) IN221113: Enercon (
(7) IN221017: Cipla Limited filed opposition on April 08, 2009 against Glaxo’s Indian Patent No. 221017 protecting anti-cancer drug molecule Lapatinib. This is the second opposition filed against Glaxo’s Lapatinib product by Cipla.
(8) IN220287: Ranbaxy Laboratories Limited filed opposition on May 21, 2009 against Eli Lilly’s Indian Patent No. 220287 protecting Olanzapine pamoate salts and formulations thereof.